Bayer's oral FXIa inhibitor reduced bleeding in patients with atrial fibrillation: Study
April 4, 2022DTMT Network
German pharma major Bayer AG has recently announced that its new experimental drug asundexian reduced the bleeding rate by 67% when compared with non-vitamin K antagonist or